The Venture Codex Logo

The Venture Codex

The Mark Foundation for Cancer Research

1350 Avenue of the Americas, Suite 2902, New York, NY, 10019, United States

Overview

Accelerating cancer research for prevention, diagnosis, and treatment.

Founded

2017

Deals · 12mo

0

Links

WebsiteLinkedIn

Stage focus

Series A
Series B

Geographic focus

United States

Sector focus

—

Investment portfolio

8rounds
NAMEDATESIZE
Accent Therapeutics
Jan 2024Participated
$75 MSeries C
Vicinitas Therapeutics
Jul 2022Participated
$65 MSeries A
Immunitas Therapeutics
Aug 2021Participated
$58 MSeries B
Interius BioTherapeutics
May 2021Participated
$76 MSeries A
C2i Genomics
Apr 2021Participated
$100 MOther Equity
C2i Genomics
Jun 2020Participated
$12 MSeries A
Accent Therapeutics
Apr 2020Participated
$63 MSeries B
Verseau Therapeutics
Oct 2019Participated
$50 MOther Equity
Accent Therapeutics
Jan 2024Participated
$75 MSeries C
Vicinitas Therapeutics
Jul 2022Participated
$65 MSeries A
Immunitas Therapeutics
Aug 2021Participated
$58 MSeries B
Interius BioTherapeutics
May 2021Participated
$76 MSeries A
C2i Genomics
Apr 2021Participated
$100 MOther Equity
C2i Genomics
Jun 2020Participated
$12 MSeries A
Accent Therapeutics
Apr 2020Participated
$63 MSeries B
Verseau Therapeutics
Oct 2019Participated
$50 MOther Equity
8
Items
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

The Mark Foundation for Cancer Research: 8 funding rounds are recorded in the selected participation categories.All available history.
The Mark Foundation for Cancer Research: 8 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Series A03
Series B02
Series C+01
Other Equity02

Monthly Deal Activity

The Mark Foundation for Cancer Research: 8 deals are recorded across 85 months.All available history.
The Mark Foundation for Cancer Research: 8 deals are recorded across 85 months. All available history
MonthDeals
Oct '191
Nov '190
Dec '190
Jan '200
Feb '200
Mar '200
Apr '201
May '200
Jun '201
Jul '200
Aug '200
Sep '200
Oct '200
Nov '200
Dec '200
Jan '210
Feb '210
Mar '210
Apr '211
May '211
Jun '210
Jul '210
Aug '211
Sep '210
Oct '210
Nov '210
Dec '210
Jan '220
Feb '220
Mar '220
Apr '220
May '220
Jun '220
Jul '221
Aug '220
Sep '220
Oct '220
Nov '220
Dec '220
Jan '230
Feb '230
Mar '230
Apr '230
May '230
Jun '230
Jul '230
Aug '230
Sep '230
Oct '230
Nov '230
Dec '230
Jan '241
Feb '240
Mar '240
Apr '240
May '240
Jun '240
Jul '240
Aug '240
Sep '240
Oct '240
Nov '240
Dec '240
Jan '250
Feb '250
Mar '250
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '250
Oct '250
Nov '250
Dec '250
Jan '260
Feb '260
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

The Mark Foundation for Cancer Research: Health & Life Sciences is the largest displayed sector by deal count (8 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

The Mark Foundation for Cancer Research: Health & Life Sciences is the largest displayed sector by deal count (8 deals). All available history
SectorDeals
Health & Life Sciences8

Deal Size Distribution

The Mark Foundation for Cancer Research: 8 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

The Mark Foundation for Cancer Research: 8 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M0
$5M-$10M0
$10M-$25M1
$25M-$50M0
$50M-$100M6
$100M-$250M1
$250M-$500M0
$500M-$1B0
$1B+0

Deals By Geography

The Mark Foundation for Cancer Research: United States has the largest recorded deal count among the displayed regions (8 deals).All available history.

Top 1 of 1 regions; European countries are grouped as Europe.

The Mark Foundation for Cancer Research: United States has the largest recorded deal count among the displayed regions (8 deals). All available history
RegionDeals
United States8
The Mark Foundation for Cancer Research: 20 co-investors are shown, with Alexandria Venture Investments sharing 3 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

The Mark Foundation for Cancer Research: 20 co-investors are shown, with Alexandria Venture Investments sharing 3 recorded deals. All available history
Co-investorShared deals
Alexandria Venture Investments3
Droia Ventures3
Google Ventures3
AbbVie Ventures2
Agent Capital2
Atlas Venture2
Casdin Capital2
EcoR1 Capital2
Longwood Fund2
NFX2
NS Investment2
The Column Group2
120 Capital1
20/20 HealthCare Partners1
3SBio1
American Cancer Society1
Andreessen Horowitz1
Bain Capital Life Sciences1
Berkeley Catalyst Fund1
BrightEdge1

Investment Strategy

The Mark Foundation for Cancer Research: Led accounts for 0% and participating for 100% of round participation.All available history.
The Mark Foundation for Cancer Research: Led accounts for 0% and participating for 100% of round participation. All available history
CategoryDeals (count)Share (%)
Led00%
Participating8100%
The Mark Foundation for Cancer Research: Single-lead accounts for 0% and co-led for 0% of lead dynamics.All available history.
The Mark Foundation for Cancer Research: Single-lead accounts for 0% and co-led for 0% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead00%
Co-led00%

Lead dynamics requires at least one led deal in this range

Team

Anna Turetsky

Principal and Venture Investments

Raymond N. DuBois

Executive Chairman

Ryan Schoenfeld

CEO